{
    "clinical_study": {
        "@rank": "38612", 
        "arm_group": [
            {
                "arm_group_label": "Add furosemide/no spironolactone", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Add metolazone/no spironolactone", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Add furosemid/spironolactone", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Add metolazone/spironolactone", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effectiveness and safety of diuretics add-on strategy in chronic heart\n      failure patients"
        }, 
        "brief_title": "A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Congestive Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. dyspnea at rest or minimal activity\n\n          2. tachypnea (respiratory rate > 20/min) or rales or pulmonary edema on chest X-ray\n\n        Exclusion Criteria:\n\n          1. hospitalization for acute heart failure decompensation\n\n          2. cardiogenic shock (Systolic Blood Pressure < 80mmHg)\n\n          3. Need or plan for renal replacement therapy (dialysis, kidney transplant)\n\n          4. serum creatine level > 2.5mg/dl\n\n          5. serum potassium (K+) > 5.5mg/dl\n\n          6. Age > 80 years old or poor compliance patients\n\n          7. allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics\n\n          8. life expectancy < 6 months (e.g. metastatic malignancy, liver cirrhosis)\n\n          9. pregnancy or women at age of childbearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047422", 
            "org_study_id": "4-2013-0808"
        }, 
        "intervention": [
            {
                "arm_group_label": "Add furosemide/no spironolactone", 
                "description": "furosemide (doubling previous furosemide dose)", 
                "intervention_name": "Furosemide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Add metolazone/no spironolactone", 
                "description": "metolazone (add 2.5mg qod)", 
                "intervention_name": "metolazone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Add furosemid/spironolactone", 
                "description": "spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)", 
                "intervention_name": "furosemid/spironolactone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Add metolazone/spironolactone", 
                "description": "no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)", 
                "intervention_name": "metolazone/spironolactone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diuretics", 
                "Furosemide", 
                "Metolazone", 
                "Spironolactone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Heart failure, diuretics, kidney, glomerular filtration rate", 
        "lastchanged_date": "January 26, 2014", 
        "location": {
            "contact": {
                "email": "smkang@yuhs.ac", 
                "last_name": "Seok-Min Kang, MD", 
                "phone": "82-2-2228-8450"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "other_outcome": [
            {
                "description": "body weight change, symptoms & signs change", 
                "measure": "body weight change", 
                "safety_issue": "No", 
                "time_frame": "from admission to HOD#4"
            }, 
            {
                "description": "urine creatinine change, serum & urine electrolyte change, biomarkers change", 
                "measure": "urine creatinine change", 
                "safety_issue": "No", 
                "time_frame": "from admission to HOD#4"
            }, 
            {
                "description": "clinical outcomes ( all-cause mortality, all-cause rehospitalization, start of renal replacement therapy)", 
                "measure": "clinical outcomes", 
                "safety_issue": "No", 
                "time_frame": "at 90 days after discharge"
            }
        ], 
        "overall_contact": {
            "email": "smkang@yuhs.ac", 
            "last_name": "Seok-Min Kang, MD", 
            "phone": "82-2-2228-8450"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "efficacy of diuretics add-on therapy, urine output change", 
            "measure": "urine output change", 
            "safety_issue": "No", 
            "time_frame": "from admission to Hospital Day (HOD)#4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047422"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "safety of diuretics add-on therapy, serum creatinine change", 
            "measure": "serum creatinine change", 
            "safety_issue": "No", 
            "time_frame": "from admission to HOD#4"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}